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B R I E F  R E P O R T
Short-Term Recovery Trajectories of Acute Flares in Knee 
Pain: A UK-Netherlands Multicenter Prospective Cohort 
Analysis
Martin J. Thomas,1  Dahai Yu,2  Elaine Nicholls,2  Sita Bierma-Zeinstra,3  Philip G. Conaghan,4   
Karen J. Stoner,5 Tuhina Neogi,6  Emma L. Parry,2  and George Peat2
Objective. To identify distinct recovery trajectories of acute flares of knee pain and associated participant 
characteristics.
Methods. Data were from the FLARE randomized controlled trial, a multicenter trial in 27 primary care centers 
in the UK and Netherlands of 3 regimes of oral nonsteroidal antiinflammatory therapy for acute flares of knee pain. 
Individuals with a history of inflammatory/crystal arthritis, fibromyalgia, and chronic pain syndrome were excluded. 
Latent class growth analysis was applied to measures of pain intensity repeated over 5 days to identify distinct 
recovery trajectories. The concurrent courses of interference with activity, stiffness, and swelling for each trajectory 
group were modelled using generalized estimating equations. Participant age, sex, obesity, and osteoarthritis 
diagnosis were described for each trajectory group.
Results. A total of 449 participants were included (median age 55 years, 41% female, 35% obese, and 42% 
diagnosed with osteoarthritis). A 6-group cubic model was deemed optimal, with trajectories distinguished by rate 
of pain reduction and absolute level at final measurement. At the extremes were rapid and near-complete resolution 
(n = 41, 9%) and persistent, high pain (n = 25, 6%), but most participants showed a reduction and plateau in pain 
severity within 3–5 days. Within each pain trajectory group, interference with activity, stiffness, and swelling followed 
the same course as pain. Baseline characteristics did not differ substantially between trajectory groups.
Conclusion. Even under a well-adhered to regime of oral nonsteroidal antiinflammatory medication, recovery 
following acute flares of knee pain is heterogeneous. Our observations that favorable trajectories are apparent within 
3–5 days can help to inform treatment decision-making in the patient–health care professional consultation.
INTRODUCTION
There is increasing recognition that the natural history of 
 osteoarthritis pain can include intermittent episodes of intense 
pain (1). Focus groups of people with hip or knee osteoar-
thritis have suggested that in the early stages of the disease 
these episodes may be relatively predictable and associated 
with high-impact activities but in later stages can become 
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unpredictable and distressing (1). The underlying nature of these 
episodes, including the role of inflammation, is still poorly under-
stood, and while a common terminology has yet to be agreed 
on (2), patients often use the terms “flares” or “flare-ups” to 
describe these phenomena, and this is the term under which a 
new Outcome Measures in Rheumatology initiative has recently 
been launched (3).
Part of the unpredictability of flares for patients and health 
care professionals is knowing how long they will last. A single 
one-size-fits-all answer is unlikely to be adequate. Long-term 
studies have demonstrated that there is no single long-term 
course for osteoarthritis symptoms (4–6), and our hypothe-
sis was that this diversity would be true also of the short-term 
course of acute flares. Using a unique trial data set that col-
lected daily measurements from participants experiencing a flare 
in knee pain, we sought to identify distinct short-term recovery 
trajectories of knee pain flares to describe the accompanying 
changes over time in self-reported function, stiffness, and swell-
ing, and to explore any participant characteristics associated 
with trajectory groups.
MATERIALS AND METHODS
Study design. The current study used data from a pub-
lished randomized controlled trial (RCT), the FLARE RCT (7). The 
trial was a multicenter, randomized, double-blind, 3-arm design 
testing for noninferiority by comparing a novel lipid formulation of 
ibuprofen 1,200 mg/day with standard ibuprofen soft-gel cap-
sules of 1,200 mg/day or 2,400 mg/day. Participants had 5 days 
of treatment, with day 0 as baseline (no medication), and day 1 
as the first treatment day. A total of 27 primary care general prac-
tices were recruited across the UK and The Netherlands. Peo-
ple with a history of knee pain flares were identified via medical 
record review and local community advertising. Participants were 
screened at local study sites to determine eligibility and invited 
to return within 24 hours if they experienced a knee pain flare 
for enrollment and randomization. Independent ethics approval 
was obtained in both countries (UK: National Research Ethics 
Service Committee East Midlands, Northampton; Netherlands: 
Independent Review Board, Nijmegen). All participants gave writ-
ten informed consent.
Study population. Community-dwelling adults ages 
40–70 years with a history of ≥1 knee pain flare episode in the last 
12 months (with or without treatment), who experienced a new 
knee pain flare with severity ≥5 on a 0–10 numerical rating scale 
(NRS), and who attended a baseline assessment within 24 hours 
of onset, were eligible to take part. Individuals were excluded if 
they had recent serious illness, fracture, a history of serious heart 
problems or clinically significant cardiovascular disease, inflam-
matory arthropathies (including gout), fibromyalgia, chronic pain 
syndrome, current selective serotonin reuptake inhibitor medica-
tion, significant injury or surgery to the knee, recent intraarticular 
corticosteroid injection into the index knee or systematic gluco-
corticoids, body mass index (BMI) >39 kg/m2, and use of any 
pain medication within 7 days of study baseline.
Data collection and outcomes of interest. Data 
collection included age, sex, BMI, participant self-reported 
osteoarthritis status confirmed by physician questioning, oral 
antiinflammatory regime allocation, baseline and posttreatment 
Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) NRS (8) scores for pain (0–50), stiffness (0–20), 
and function (0–170), self-reported number of days since flare 
started, knee flare response (proportion of flares “fully controlled/
under control” by the end of the 5-day treatment course one), 
the proportion beginning the second 5-day course of oral antiin-
flammatory medication from day 6, and the proportion of 100% 
adherence with treatment course one. Participant-reported 
average daily pain intensity, pain interference with participant- 
nominated activity, stiffness after sitting, lying, or resting, and 
swelling (all on a 0–10 NRS) were also collected prospectively 
each day to day 5 at the same time of day as the baseline ques-
tionnaire was completed.
Statistical analyses. Latent class growth analysis (LCGA) 
was used to model individual pain intensity trajectories over time 
and was based on the sample of participants with pain intensity 
data at all timepoints. Pain intensity was analyzed with a cen-
sored normal distribution. A 1-group quadratic model was initially 
fitted to the data because we hypothesized that the trajecto-
ries in this data set would be nonlinear. A search for the opti-
mal quadratic model was conducted by sequentially increasing 
the number of groups by 1 until model fit no longer improved. 
We also explored whether the same optimum model would 
have been concluded if a cubic model had been assumed, and 
if any group-specific cubic terms were statistically significant 
(P < 0.05). Model fit statistics included the Akaike information 
criterion (AIC), the Bayesian information criterion (BIC), and the 
sample-size adjusted BIC (ABIC), with lower absolute values of 
statistics indicating better model fit. Entropy (value 0–1) was used 
to indicate how well the model predicted class membership, with 
values >0.8 desirable (9). We also considered that for a model 
to be optimal, all class sizes should be >5% of the total sample 
SIGNIFICANCE & INNOVATIONS
• Recovery trajectories following flares of knee pain 
managed with oral nonsteroidal antiinflammatory 
medication are heterogeneous and difficult to pre-
dict based on participant characteristics.
• The identification of favorable trajectories within 
3–5 days can be used to inform treatment deci-
sion-making in the patient–health care professional 
consultation.
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(to minimize the potential for the specific class not to be repli-
cated in another data set) and that class-specific average poste-
rior probabilities were >0.7 (10,11).
To check whether a global solution had been reached in the 
estimation algorithm, models were rerun using 5,000 different 
starting values to examine whether the same model likelihood was 
attained irrespective of starting values. If in >2 final-stage solutions 
the highest log likelihood was repeated, a global solution was then 
concluded (12). We also conducted sensitivity analyses to check 
whether model results were consistent when the data were mod-
eled using growth mixture models (13), i.e., when the variance 
and covariance of the growth factors was freely estimated, rather 
than fixed at zero as in LCGA, or when participants with pain- 
intensity data for at least 1 time point were included in the analysis. 
All models were fitted using maximum likelihood estimation so that 
when missing data were included in the model, we assumed them 
to be missing at random.
Trajectory membership was further examined by plotting the 
derived trajectories based on the number in the smallest trajectory 
group and generating a random sample of the same number for 
each of the other 5 derived trajectories. This process was per-
formed to visually judge the extent to which individual trajectories 
followed the average trajectory for each group.
In each latent group, the marginal estimation of pain interfer-
ence, with participant-nominated activity at each time point as the 
outcome, was analyzed using generalized estimating equations 
incorporating age, sex, categorical variable for trajectory group, 
and a cubic term for time as predictors. Predicted mean estimates 
at each time point were presented with 95% confidence inter-
vals, calculated using robust standard errors. This process was 
repeated for self-reported stiffness and swelling outcomes.
Demographics, clinical characteristics, and the proportion of 
participants reporting their flare as “fully controlled/under control” 
at day 5 were described by trajectory group. Unadjusted multino-
mial logistic regression was used to explore baseline predictors 
of the trajectory group. Adjusted models were not considered 
because our sample size was too small for such an analysis to 
be reliable. Finally, we conducted a subgroup analysis in which 
we repeated the LCGA in those patients with a diagnosis of oste-
oarthritis. This procedure was to determine whether the findings 
in the primary analysis could reasonably be generalized to cases 
diagnosed with osteoarthritis. Data management and analy-
sis were performed using Stata MP software, version 14.1, and 
Mplus, version 8.1 (14).
RESULTS
Study population included. Of 462 study participants 
enrolled and randomized between March 2015 and August 2016, 
13 cases had missing data at 1 or more follow-up time points, 
leaving 449 participants eligible for inclusion in the complete-case 
analysis.
Trajectories of recovery. A cubic 6-group model was 
deemed the optimal solution based on low AIC, BIC, and ABIC, 
and high entropy and average posterior probabilities (see Sup-
plementary Table 1, available on the Arthritis Care & Research 
website at http://onlin elibr ary.wiley.com/doi/10.1002/acr.24088/ 
abstract). Group membership ranged in size from n = 25 (5.6%, 
group 6) to n = 143 (31.8%, group 4). In all 6 groups, individual 
participant trajectories showed a similar spread around the mean, 
supporting the model fit (see Supplementary Figure 1, available 
at http://onlin elibr ary.wiley.com/doi/10.1002/acr.24088/ abstract). 
The cubic 6-group growth mixture model, with all parameters 
freely estimated, failed to converge to a global solution. However, 
constraining the variance around the quadratic and cubic model 
terms produced a global solution, albeit where the optimal num-
ber of classes was inconsistent across different indices (see Sup-
plementary Tables 2 and 3 and Supplementary Figure 2, available 
at http://onlin elibr ary.wiley.com/doi/10.1002/acr.24088/ abstract). 
A similar solution appeared optimal when analysis was restricted 
to participants with a diagnosis of osteoarthritis (see Supplemen-
tary Table 4 and Supplementary Figure 3, available at http://onlin 
elibr ary.wiley.com/doi/10.1002/acr.24088/ abstract). The results 
were also consistent between the complete-case analysis and the 
analysis incorporating missing data, given that the rate of missing 
data in the study was low (3%).
Groups were differentiated mainly on the rate of recovery 
and pain level attained at day 5 (Figure 1). Two groups (group 
5 [n = 104] and group 6 [n = 25]) showed modest or minimal 
reductions in pain and, despite high reported levels of adherence 
Figure 1. Pain score by group-based trajectory membership 
(n = 449). On the x-axis, 0 = baseline (no medication), and day 1 
is the first treatment day. Group 1 (n = 41) □; Group 2 (n = 38) ○; 
Group 3 (n = 98) ◊; Group 4 (n = 143) ●; Group 5 (n = 104) ♦; 
Group 6 (n = 25) ■.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































RECOVERY TRAJECTORIES IN ACUTE KNEE PAIN FLARES |      1691
to 5 days of oral nonsteroidal antiinflammatory drugs (NSAIDs), 
remained at high levels of pain. All other groups showed different 
rates of pain reduction, with 3 groups experiencing pain scores of 
<3 on a 0–10 NRS after 5 days of treatment.
Scores for severity of pain interference with participant- 
nominated activity and of stiffness closely followed the trajectories 
in pain severity (see Supplementary Figures 4 and 5, available on 
the Arthritis Care & Research website at http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24088/ abstract). Self-reported severity of 
swelling also followed a similar course to pain severity, although 
scores for swelling were systematically lower than for pain severity, 
particularly at baseline (see Supplementary Figure 6, available at 
http://onlin elibr ary.wiley.com/doi/10.1002/acr.24088/ abstract). Of 
note, participants who experienced the most rapid and complete 
resolution of pain (group 1) had much lower self-reported swelling 
at baseline than other trajectory groups.
Comparison of participant characteristics between 
trajectory groups. Groups differed on WOMAC subscale 
scores at baseline and at follow-up, and this variation was 
reflected in differences in the proportion who reported their 
flare as being “fully controlled/under control” at day 5 and opt-
ing to begin a second course of oral NSAIDs (Table 1 and Sup-
plementary Tables 5 and 6, available on the Arthritis Care & 
Research website at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24088/ abstract). Sex, osteoarthritis diagnosis, days since 
the flare started, and NSAID regime were not strongly associ-
ated with group membership. Differences observed between 
groups for age and BMI did not follow a clear pattern and were 
not statistically significant (Table 1 and Supplementary Tables 5 
and 6, available at http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24088/ abstract). While self-reported adherence with the 
NSAID regime was generally high in all groups (≥88%), statisti-
cally significant between-group differences were observed, with 
the lowest adherence seen among the group with the fastest 
reductions in pain, suggesting discontinuation of NSAIDs due to 
symptom resolution.
DISCUSSION
Our findings demonstrate that acute flares of knee pain do 
not follow a predictable, set course. From pain levels that were 
initially moderate  to severe, we identified a range of recovery tra-
jectories from rapid and substantial symptom improvement within 
3 days to minimal short-term improvement. Unfortunately, we 
found no strong predictors of recovery trajectory, although data 
on several potentially relevant determinants of outcome (e.g., 
occupational exposures, low mood) were not collected. Since all 
participants in our study received a 5-day course of oral NSAID 
preparations of comparable efficacy, and with high self-reported 
adherence, we can be more confident that differences in recov-
ery trajectory are unlikely to be explained simply by differences in 
treatment. Indeed, we should recognize that the natural course 
of flares under less optimized, real-world conditions is likely to be 
less favorable than observed in this study. Furthermore, with the 
absence of a no-treatment control for comparison, whether the 
same patterns and frequency of patterns would occur under other 
or no treatment conditions cannot be known.
The age of participants in our study may be important. 
Studies of long-term symptom trajectories in knee pain have 
recruited participants with a mean age ranging from 56 to 71 
years. The age of participants in the current study was at the 
lower end of this range (median age 55 years) and comparable 
to that of the Cohort Hip and Cohort Knee (CHECK) study of 
early osteoarthritis (4). Following the exclusion of potential partic-
ipants with a history of inflammatory/crystal arthropathy, fibromy-
algia, and chronic pain syndrome, our study findings most likely 
reflect acute flares in relatively early knee osteoarthritis. Thus, our 
observations provide some empirical support for the qualitative 
finding of Hawker et al that flares may be present in an early 
phase of osteoarthritis (1).
In this study, acute flares were self-declared by participants, 
a pragmatic decision in the absence of more robust criteria, and 
one with some face and construct validity. Nevertheless, the 
flares are still likely to represent heterogeneous underlying patho-
physiologic processes. Future studies using imaging to assess 
the role of joint inflammation, for example, may be insightful. The 
resolution of pain appeared to track the resolution of self-reported 
swelling, and those participants with the most rapid pain recovery 
had the least swelling at baseline, consistent with the proposal of 
Marty et al (15) that knee effusion is an important (but not essen-
tial) component of knee osteoarthritis flares. We acknowledge 
that the 5-day study period was short, and future studies with 
longer follow-up could more accurately establish both the time 
to resolution of flares (particularly for those groups whose pain 
did not resolve over 5 days) and the frequency and interval of 
recurrence.
What are the implications of this research? We provide some 
evidence that could inform the conversation between health care 
professionals and patients about the usual expected course of 
a flare but also when an unfavorable trajectory might become 
apparent. Our study does not provide evidence on how these 
should be managed. However, we note that if achieving rapid 
and substantial symptom improvement in all patients is unreal-
istic, an alternative is to attempt to shift patients’ flares into an 
adjacent, more favorable trajectory. This more modest goal could 
still produce important reductions in disability days and time spent 
in moderate-to-severe pain.
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